This study shows that an abnormal karyotype is present in approximately one third of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have poor survival independently from the MYSEC-PM risk stratification and need to be identified. These findings reinforce the utility of assessing cytogenetics in SMF.
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Mora B;Rumi E;Maffioli M;Cavalloni C;Merli M;Pietra D;Cazzola M;
2018-01-01
Abstract
This study shows that an abnormal karyotype is present in approximately one third of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have poor survival independently from the MYSEC-PM risk stratification and need to be identified. These findings reinforce the utility of assessing cytogenetics in SMF.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
